Literature DB >> 18359469

In utero programming of adult vascular function in transgenic mice lacking low-density lipoprotein receptor.

Josje Langenveld1, Fanxian Lu, Egle Bytautiene, Garland D Anderson, George R Saade, Monica Longo.   

Abstract

OBJECTIVE: The objective of this study was to examine the role of maternal hypercholesterolemia in fetal programming of adult vascular function using transgenic mice lacking the low-density lipoprotein receptor (LDLR). STUDY
DESIGN: Homozygous LDLR knockout mice (B6.129S7-Ldlr(tm1Her)/J, LDLR(-/-KO)) and their wild-type controls (C57BL/6J, LDLR(+/+WT)) were cross-bred to produce 4 litter groups: LDLR(-/-KO), maternally derived heterozygous (LDLR(+/-Mat)), paternally derived heterozygous (LDLR(+/-Pat)) and LDLR(+/+WT). Female and male offspring were killed at 10-12 weeks of age, and carotid arteries were used for in vitro experiments.
RESULTS: The dose responses to phenylephrine were significantly higher in LDLR(-/-KO) and LDLR(+/-Mat) male offspring. The contractile responses to phenylephrine in female mice were significantly increased only in the LDLR(-/-KO) offspring. Maximal Ca(2+) contraction was higher in LDLR(-/-KO) male and female offspring.
CONCLUSION: Despite being genomically similar, heterozygous offspring that developed in a hypercholesterolemic maternal environment had abnormal vascular responses later in life compared with those that developed in a normal environment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359469     DOI: 10.1016/j.ajog.2008.01.057

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

Review 1.  Effect of maternal cardiovascular conditions and risk factors on offspring cardiovascular disease.

Authors:  Wulf Palinski
Journal:  Circulation       Date:  2014-05-20       Impact factor: 29.690

Review 2.  High Fat Programming and Cardiovascular Disease.

Authors:  Marlon E Cerf
Journal:  Medicina (Kaunas)       Date:  2018-11-13       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.